Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellectricon Launches Grant to Fund Electroporation-based Research

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
New Cellaxess® Project Grant supports advanced research projects.

As a provider of advanced cell-based screening technologies and services, Cellectricon is inviting researchers to apply for the recently launched Cellaxess Project Grant. The Grant is open to any scientist or research group wanting to capitalize on the advanced electromanipulation capabilities of the Cellaxess® platform for the cellular delivery of non-genetic material, particularly small molecules and peptides. Winners will be selected from two categories, basic and applied cell-based research, and will receive the Cellaxess ACE platform, along with all consumables and reagents, for a fully supported project. Interested groups should submit a research proposal by Wednesday 31st July, explaining how they intend to use the Cellaxess technology in their research project, using the application form available on Cellectricon’s website.

The Cellaxess electroporation system, which can be used for the in-situ transfection of any adherent cell-type, ensures minimal cell processing for perfectly retained cell function and morphology. As such, the platform is ideal for the delivery of non-genetic material, including antibodies, peptides and other small molecules, to challenging cells such as primary and IPS-derived neuronal cell types. Cellectricon welcomes proposals that exploit these unique capabilities of the Cellaxess system and, via the Cellaxess Project Grant, is keen to support and develop the proprietary work of research groups worldwide. Helping to expand the scope of such research, the Grant provides a unique opportunity for scientists to access cutting-edge technologies and gain first-hand advice from Cellectricon’s expert team.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
The company, a leading provider of advanced cell-based discovery services, has appointed Dr Edwin Johnson, Director of The Stockholm Brain Institute, as the first member of its new Scientific Advisory Board.
Thursday, July 09, 2015
UCL’s Novel Approach to Research in Biologically-Relevant Models
Cellectricon and UCL unite to present a webinar, March 27, 11am-12pm EDT.
Wednesday, March 19, 2014
Cellectricon Announces Project Grant Winners
The grant was awarded for project proposals utilizing Cellectricon’s Cellaxess ACE technology for the delivery of non-genetic material to adherent cells and cultures.
Thursday, September 19, 2013
Presenting Phenotypic Screening Strategies for Chronic Pain Research
Cellectricon explores novel phenotypic assay designs in a webinar, 5 September, 11am-12pm (EDT).
Wednesday, August 21, 2013
Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
Discovery services will be based on automated cellular electric field manipulation for novel screening applications.
Wednesday, June 13, 2012
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!